Research Article
COlchicine to Prevent PeriprocEdural Myocardial Injury in Percutaneous Coronary Intervention (COPE-PCI): Coronary Microvascular Physiology Pilot Substudy
Table 1
Baseline patient characteristics and pre-PCI medication use, by study drug randomization.
| | Baseline characteristics | Colchicine (n = 24) | Placebo (n = 26) |
| | NSTEMI vs. SA presentation | | NSTEMI | 11 (46) | 12 (46) | | SA | 13 (54) | 14 (54) | | Baseline patient characteristics | | Age, y | 67.0 ± 10.2 | 62.6 ± 11.7 | | Male | 16 (67) | 18 (69) | | Obese (BMI >30) | 12 (50) | 19 (73) | | Current smoker | 4 (17) | 6 (23) | | Hypertension | 13 (54) | 15 (58) | | Dyslipidaemia | 15 (63) | 20 (77) | | Diabetes mellitus | 8 (33) | 5 (19) | | Prior myocardial infarction | 4 (17) | 4 (15) | | Prior percutaneous coronary intervention | 3 (13) | 4 (15) | | Family history of ischaemic heart disease | 11 (46) | 18 (69) | | Pre-PCI medication use | | Aspirin | 24 (100) | 26 (100) | | P2Y12 inhibitor | 23 (96) | 25 (96) | | Statins | 23 (96) | 22 (85) | | Beta-blockers or/& Ca-channel blocker | 16 (67) | 22 (85) | | Angiotensin-converting enzyme inhibitors | 9 (38) | 12 (46) | | Angiotensin–II–receptor antagonists | 5 (21) | 7 (27) | | Nitrates | 2 (8) | 2 (8) |
|
|
Values are n (%) or mean ± SD.
|
